secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2025-04-11T23:59:59+00:00
Accession:  0001104659-25-034210
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO enters retention agreements with three top executives; bonuses tied to CHASE trial data
--------------------------------------------------------------------------------

- Retention bonuses: Bazemore $281,190, Reumuth $234,000, Brazzell $260,000.
- Bonuses payable by April 18, 2025; clawback if executive resigns or is terminated for cause before earlier of Sept 30, 2025 or CHASE trial topline data announcement.
- CHASE trial of KPI-012 topline data expected Q3 2025 per exhibit.
- Coverage includes Interim CEO, CFO, and Head of R&D/CMO, focusing on retaining key personnel ahead of trial results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000110465925034210/0001104659-25-034210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000110465925034210/tm2512021d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-034210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer